Beta Bionics, Inc. BBNX
13.32 USD -1.01 (-7.05%)
Regular-session close
13.32 0.00 0.00%
After hours · Nov 19, 4:39 PM ET
13.02 Day range 15.07
8.80 52-week range 32.71
- YTD
- -56.28%
- 1 year
- -51.95%
News
zacks.com BBNX & SENS Launch Eversense 365 Integration With iLet Bionic Pancreas Beta Bionics launches iLet Bionic Pancreas integration with Eversense 365, offering more CGM options and boosting growth prospects in the diabetes care market.
globenewswire.com Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration Eversense 365 now works with iLet, combining a year of accurate glucose monitoring with fully adaptive, automated insulin delivery to reduce the demands of managing diabetes
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…benzinga.com TD Cowen Maintains Hold on Beta Bionics, Raises Price Target to $21 TD Cowen analyst Mathew Blackman maintains Beta Bionics (NASDAQ:BBNX) with a Hold and raises the price target from $18 to $21.
benzinga.com Piper Sandler Reiterates Overweight on Beta Bionics, Raises Price Target to $24 Piper Sandler analyst Matt O'Brien reiterates Beta Bionics (NASDAQ:BBNX) with a Overweight and raises the price target from $20 to $24.
benzinga.com Beta Bionics Q3 2026 Earnings Call Transcript Beta Bionics (NASDAQ:BBNX) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG)…benzinga.com Beta Bionics Raises FY2026 Sales Guidance from $121.000M-$126.000M to $124.000M-$126.000M vs $126.626M Est Beta Bionics (NASDAQ:BBNX) raises FY2026 sales outlook from $121.000 million-$126.000 million to $124.000 million-$126.000 million vs $126.626 million estimate.
benzinga.com Beta Bionics Q3 EPS $(0.52) Beats $(0.53) Estimate, Sales $35.505M Beat $34.722M Estimate Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.53) by 1.89 percent. This is a 57.58 percent decrease over losses of $(0.33)…
